Heron Therapeutics Q2 2024 GAAP EPS $(0.06) Misses $(0.04) Estimate, Sales $36.024M Beat $35.888M Estimate
Portfolio Pulse from Benzinga Newsdesk
Heron Therapeutics (NASDAQ:HRTX) reported Q2 2024 GAAP EPS of $(0.06), missing the $(0.04) estimate, but achieved sales of $36.024M, beating the $35.888M estimate. Sales increased by 13.42% year-over-year.
August 06, 2024 | 8:17 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Heron Therapeutics reported a Q2 2024 GAAP EPS of $(0.06), missing the $(0.04) estimate, but achieved sales of $36.024M, beating the $35.888M estimate. Sales increased by 13.42% year-over-year.
The mixed earnings report, with a miss on EPS but a beat on sales and significant year-over-year growth, is likely to result in a neutral short-term impact on the stock price. Investors may weigh the EPS miss against the positive sales performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100